To elucidate the NLGP's effect on immune-mediated tumor cell killing, first, we checked the CD8+ T cell activation status in EMM and found elevated proportion of splenic CD8+, CD8+Ki67+, CD8+CD44+, CD8+IL-2+, and CD8+IFN-γ+ T cells in NLGP-treated cohort (Figures S4BA,B), which led us to hypothesize that activated CD8+ T cells might infiltrate into the lungs to reduce metastasis. The gene discussed is CD8A; the disease is neoplasm.